Evaluating the efficacy and safety of MDMA for the treatment of Post Traumatic Stress Disorder: a systematic review
Megha Kodancha, Houssein Chahrour, Charles Carey, Hiva Fazeli, Anahita Azadian, Sten Kajitani
UCC Student Medical Journal October 17, 2025 DOI: 10.33178/smj.2025.1.4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Randomized Open-label Peer reviewed |
|---|---|
| Population | Individuals with chronic, treatment-resistant posttraumatic stress disorder (PTSD) |
| Intervention | MDMA-assisted psychotherapy |
| Duration | 12-month follow-up |
| Topics | MDMA PTSD |
| Keywords | Randomized controlled trial Clinical psychology Extant taxon Psychotherapist Adverse effect Systematic review Clinical trial Placebo response Meta-analysis Poison control |
| Key findings | MDMA-assisted psychotherapy significantly reduces PTSD symptoms compared to placebo plus psychotherapy, with effects sustained for at least 12 months. |
Abstract
Background: Posttraumatic stress disorder (PTSD) affects approximately 5-7% of the population, with conventional treatments often proving inadequate for some patients. Recent studies suggest that methylenedioxymethamphetamine (MDMA) combined with psychotherapy may offer a novel therapeutic approach. This systematic review evaluates the efficacy and safety of MDMA-assisted psychotherapy for the treatment of PTSD in individuals with chronic, treatment-resistant forms of the disorder.
Methods: A comprehensive search was conducted in PubMed, OVID, Scopus, Cochrane databases, and select reference lists for randomized controlled trials (RCTs) evaluating MDMA as a treatment for PTSD. Eligibility criteria included RCTs with participants with confirmed PTSD diagnoses using standardized clinical assessments.
Results: In the RCT studies, there are significant reductions in PTSD symptoms (p<0.05) in those with MDMA-assisted psychotherapy compared to those with placebo and psychotherapy; dose-dependent improvements were observed in various measurements scales (specifically in CAPS-IV/CAPS-5 scores). Open-label trials further demonstrated improvements in PTSD symptoms when given MDMA-assisted therapy (p<0.05) and long-term analyses of studies demonstrated that effects of MDMA-assisted therapy were maintained for a minimum of 12 months post-intervention(p<0.05). Adverse effects were transient and mild to moderate, including anxiety, headache, fatigue, muscle tension, and insomnia.
Conclusion: Extant data suggests that MDMA-assisted psychotherapy for PTSD demonstrates significant symptom reduction, with sustained efficacy up to 12 months post-treatment. Functional unblinding is a major methodological challenge, which makes it difficult to interpret the magnitude of the effect MDMA has in the treatment of treatment-resistant PTSD. Future research should refine methodologies and explore long-term safety and efficacy in diverse populations.